Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pharmacokinetic Phase I study Comparing Docecal and Taxotere in Patients with Metastatic Breast Cancer

X
Trial Profile

A Pharmacokinetic Phase I study Comparing Docecal and Taxotere in Patients with Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics; Registrational
  • Sponsors Vivesto
  • Most Recent Events

    • 31 May 2020 Results assessing PK, safety and early activity from two clinical studies: EudraCT2012-005161-12 and EudraCT2013-004889-33 presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 24 Jun 2019 According to an Oasmia Pharmaceutical media release, this study indicates that Docecal is bioequivalent with Taxotere (AUC0-last and Cmax) with regards to the total fraction of docetaxel in plasma.
    • 24 Jun 2019 Results from the two clinical studies using Docecal in patients with metastatic breast cancer (CTP 293315 and CTP 293313) presented in an Oasmia Pharmaceutical media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top